UCB today announced that the company has regained all global rights to bepranemab following termination of a collaboration ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

Melbourne, Australia-based Telix Pharmaceuticals has launched Rhine Pharma, a subsidiary focused on enhancing global access ...

UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from ...

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

ICER has released its final report on treatments for transthyretin amyloid cardiomyopathy, evaluating Pfizer’s Vyndamax, ...

Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the ...

Berlin, Germany-based Ariceum Therapeutics presented promising preclinical data at EANM 2024 on its radiop5Ac-satoreotide for ...

Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and ...

Philadelphia-based SERB Pharmaceuticals has acquired Aurlumyn, the only FDA-approved treatment for severe frostbite in the ...

Otsuka Pharmaceutical (TYO: 4578) today announced positive top-line interim data from the ongoing Phase III clinical trial of ...

Japanese clinical-stage biotech Aculys Pharma announced that pitolisant (BF2.649), a histamine H3 receptor antagonist/inverse ...